Stability of Olmesartan Medoxomil Extemporaneous Suspensions
- 27 October 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 38 (1) , 3-9
Abstract
Background: Olmesartan medoxomil (OLM) is only available in the United States as tablets. The United States Pharmacopoeia (USP) has placed OLM on its priority list of preparations that require stability data to support practitioner compounding. Objective: The purpose of the study was to develop a stability-indicating assay and then determine the beyond-use date (BUD) for an extemporaneous OLM suspension. Methods: A reverse-phase high-performance liquid chromatography (HPLC) assay was developed and validated according to guidelines for USP official compounded monographs. OLM 2 mg/mL suspensions were compounded with Ora-Sweet and Ora-Plus and stored at room temperature or in a refrigerator. Suspensions were assayed periodically over 90 days for OLM concentration and observed for physical stability. The pH was measured at the beginning and end of the study. Results: The OLM concentration remained above 97% of the starting concentration for 90 days when stored in the refrigerator and above 94% of the starting concentration for 90 days when stored at room temperature. The suspension pH did not change and indicators of physical stability were unchanged for 90 days. Conclusion: OLM 2 mg/mL suspensions were chemically and physically stable at room temperature and in the refrigerator for 90 days. The BUD may be set at 90 days under either storage condition.Keywords
Funding Information
- SIUE School of Pharmacy and the SIUE Graduate School
This publication has 9 references indexed in Scilit:
- The global epidemiology of hypertensionNature Reviews Nephrology, 2020
- Development and Validation of a Stability-Indicating Liquid Chromatographic Method for Estimating Olmesartan Medoxomil Using Quality by DesignJournal of Chromatographic Science, 2015
- Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage formsEuropean Journal of Clinical Pharmacology, 2012
- Preparation and Characterization of Self-Microemulsifying Drug Delivery System of Olmesartan Medoxomil for Bioavailability ImprovementJournal of Pharmaceutics, 2012
- Development and Validation of a Discriminating In Vitro Dissolution Method for a Poorly Soluble Drug, Olmesartan Medoxomil: Comparison Between Commercial TabletsAAPS PharmSciTech, 2010
- RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditionsActa Pharmaceutica, 2010
- Stability-Indicating LC Method for the Determination of Olmesartan in Bulk Drug and in Pharmaceutical Dosage FormChromatographia, 2008
- Underdiagnosis of Hypertension in Children and AdolescentsJAMA, 2007
- A Review of the Structural and Functional Features of Olmesartan Medoxomil, An Angiotensin Receptor BlockerJournal of Cardiovascular Pharmacology, 2005